Tamio M. Fujiwara

Toyonaka, 5610825, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors.

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors.

Journal: Bioorganic & medicinal chemistry letters
Published: April 25, 2024

Barrier to Resistance of Dolutegravir in Two-Drug Combinations.

Barrier to Resistance of Dolutegravir in Two-Drug Combinations.

Journal: Antimicrobial agents and chemotherapy
Published: October 03, 2018

Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.

Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.

Journal: Antiviral research
Published: October 16, 2017

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Journal: Antimicrobial agents and chemotherapy
Published: November 19, 2014

Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Journal: Antimicrobial agents and chemotherapy
Published: November 05, 2014

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Journal: Lancet (London, England)
Published: April 05, 2014

Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups.

Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups.

Journal: Bioorganic & medicinal chemistry letters
Published: February 21, 2014

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.

Journal: HIV clinical trials
Published: October 23, 2013

Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).

Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).

Journal: Journal of medicinal chemistry
Published: July 13, 2013

Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects

Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects

Journal: The Japanese journal of antibiotics
Published: June 20, 2013

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.

Journal: Journal of medicinal chemistry
Published: January 16, 2013

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Journal: The Journal of infectious diseases
Published: December 11, 2012
Showing 1-12 of 17

Last Updated: 09/26/2026